Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
J Surg Oncol. 2012 Aug 1;106(2):204-8. doi: 10.1002/jso.23072. Epub 2012 Feb 21.
To evaluate the impact of plasminogen activator (PA) system genes, including urokinase plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms in patients with the cervical neoplasia.
In total, 336 blood samples were collected from healthy women and 136 patients with cervical neoplasia to analyze the gene polymorphisms of representative PA system genes.
There was no significant association between cervical neoplasia cases and gene polymorphisms of uPA, uPAR and PAI-1 genes as well as to the carcinogenesis of cervical if the cervical neoplasia cases were stratified to HSILs and invasive cancer cases. However, we found a mutual interaction between uPA/PAI-1 genes, which women carrying the uPA/PAI-1 CC/4G4G allele had a 1.70-fold higher risk (OR = 1.70; 95% CI 1.04-2.79) of cervical neoplasia compared with those carrying the CC/4G5G allele.
Individuals with uPA/PAI-1 CC/4G5G allele were in high susceptibility for cervical neoplasia. The combined polymorphism of uPA/PAI-1 might diminish the ability of PAI-1 to inhibiting cervical cancer carcinogenesis when PAI-1 alone as the role of inhibitor.
评估纤溶酶原激活物（PA）系统基因，包括尿激酶型纤溶酶原激活物（uPA）、uPA 受体（uPAR）和纤溶酶原激活物抑制剂-1（PAI-1）基因多态性，对宫颈癌患者的影响。
共采集 336 例健康女性和 136 例宫颈癌患者的血液样本，分析代表性 PA 系统基因的基因多态性。
未发现宫颈癌病例与 uPA、uPAR 和 PAI-1 基因的基因多态性之间存在显著关联，也未发现宫颈癌病例与宫颈癌的发生存在显著关联，如果将宫颈癌病例分层为 HSILs 和浸润性癌病例。然而，我们发现 uPA/PAI-1 基因之间存在相互作用，携带 uPA/PAI-1 CC/4G4G 等位基因的女性患宫颈癌的风险是携带 CC/4G5G 等位基因的女性的 1.70 倍（OR=1.70；95%CI 1.04-2.79）。
uPA/PAI-1 CC/4G5G 等位基因个体易患宫颈癌。当 PAI-1 单独作为抑制剂发挥作用时，uPA/PAI-1 的联合多态性可能会降低 PAI-1 抑制宫颈癌发生的能力。
